Jun 04, 2024 9:00 am EDT Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
May 13, 2024 4:05 pm EDT Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 9:15 am EDT Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
May 08, 2024 9:00 am EDT Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
May 06, 2024 9:00 am EDT Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Apr 24, 2024 9:00 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Mar 06, 2024 8:30 am EST Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 29, 2024 4:05 pm EST Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Feb 27, 2024 8:30 am EST Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy